A preliminary study on K-ras, EGFR, and B-raf mutations of esophageal squamous cell carcinoma
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Molecular targeted drugs have been widely used in clinical application which has successfully prolonged some patients’ life. Meanwhile, molecular targeted drug therapy for esophageal cancer are attracting more and more attention from doctors and experts. However, little study has been done towards the effect of this approach for treating esophageal squamous cell carcinoma. This paper, therefore, intends to explore the possibilities of applying EGFR-TKI inhibitors or anti-EGFR monoclonal antibody in esophageal squamous cell carcinoma by studying the mutations of EGFR, K-ras and B-raf in the esophageal squamous cell carcinoma tissues.
Thirty-five cases of resected specimens of diagnosed esophageal squamous cell carcinoma with complete clinical and pathological data from January to April 2009 were collected. Pyrophosphate was used for observing the mutations of EGFR, K-ras and B-raf in the esophageal squamous cell carcinoma tissues.
Examinations were undertaken respectively to the codon segment 746–754 of exon 19 in EGFR genes, codon 12 and 13 in K-ras genes as well as condon 600 in B-raf genes. No mutation was found in EGFR and B-raf genes with mutation rate 0% (0/35), all of codon 12 in K-ras genes were wild-type without any mutation, while 2 specimens of codon 13 had mutations with mutation rate of 5.71% (2/35).
In treating esophageal squamous cell carcinoma patients, all K-ras genes are expressed as wild type due to low mutation rate; cetuximab is effective due to low mutation rate of B-raf while EGFR-TKI inhibitor will not be effective enough because of low mutation rate of EGFR genes.
- Wu YL, Sun Y. Cancer management can be personalized? -Cancer genomic research in China. Chinese-German J Clin Oncol, 2006, 5: 156–158. CrossRef
- Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with efinical response to gefitinib therapy. Science, 2004, 304: 1497–1500. CrossRef
- Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350: 2129–2139. CrossRef
- Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of gefitinibin second-line treatment of advanced esophageal cancer patients. J Clin Oncol, 2006, 24: 1612–1619. CrossRef
- Guo M, Liu S, Herman JG, et al. Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450. Cancer Biol Ther, 2006, 5:152–155. CrossRef
- Guo M, Liu S, Lu F. Gefitinib-sensitizing mutations in esophageal carcinoma. N Engl J Med, 2006, 354: 2193–2194. CrossRef
- Pühringer-Oppermann FA, Stein HJ, Sarbia M. Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett’s) adenocarcinomas. Dis Esophagus, 2007, 20: 9–11. CrossRef
- Sudo T, Mimori K, Nagahara H, et al. Identification of EGFR mutations in esophageal cancer. Eur J Surg Oncol, 2007, 33: 44–48.
- Hanawa M, Suzuki S, Dobashi Y, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer, 2006, 118: 1173–1180. CrossRef
- De Vita F, Orditura M, Martinelli E, et al. A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced esophageal cancer. Br J Cancer, 2011, 104: 427–432. CrossRef
- Gonçalves A, Esteyries S, Taylor-Smedra B, et al. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer, 2008, 8: 169. CrossRef
- Lyronis ID, Baritaki S, Bizakis I. K-ras mutation, et al. HPV infection and smoking or alcohol abuse positively correlate with esophageal squamous carcinoma. Pathol Oncol Res, 2008, 14: 267–273. CrossRef
- Arber N, Shapira I, Ratan J. et al. Activation of c-K-ras mutations in human gastrointestinal tumors. Gastroenterology, 2000, 118: 1045–1050. CrossRef
- Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type B-raf is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol, 2008, 26: 5668–5670. CrossRef
- Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature, 2002, 417: 949–954. CrossRef
- A preliminary study on K-ras, EGFR, and B-raf mutations of esophageal squamous cell carcinoma
The Chinese-German Journal of Clinical Oncology
Volume 10, Issue 9 , pp 497-501
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- carcinoma of esophagus
- pyro-sequencing molecular targeted drugs